| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00702-020-02149-3 |
| P698 | PubMed publication ID | 32025811 |
| P50 | author | Hideki Mochizuki | Q87970827 |
| P2093 | author name string | Chi-Jing Choong | |
| Kousuke Baba | |||
| P2860 | cites work | Karak syndrome: a novel degenerative disorder of the basal ganglia and cerebellum | Q24676847 |
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| Alpha-synuclein in Lewy bodies | Q27860680 | ||
| Regulation of ATP13A2 via PHD2-HIF1α Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease | Q28118364 | ||
| Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure | Q28145614 | ||
| Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B | Q28346410 | ||
| Molecular Pathways of Neurodegeneration in Parkinson's Disease | Q29619903 | ||
| Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease | Q30537842 | ||
| Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis | Q33198182 | ||
| Biomonitorization of iron accumulation in the substantia nigra from Lewy body disease patients | Q33703477 | ||
| Targeting chelatable iron as a therapeutic modality in Parkinson's disease | Q33768106 | ||
| The Parkinson-associated human P5B-ATPase ATP13A2 protects against the iron-induced cytotoxicity | Q48209774 | ||
| Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. | Q48229587 | ||
| Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility | Q48393606 | ||
| Interaction of α-Synuclein with Divalent Metal Ions Reveals Key Differences: A Link between Structure, Binding Specificity and Fibrillation Enhancement | Q58484316 | ||
| Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains | Q61714001 | ||
| Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease | Q64763413 | ||
| The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity | Q64777142 | ||
| Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts | Q64786363 | ||
| Comprehensive MRI quantification of the substantia nigra pars compacta in Parkinson's disease | Q64795557 | ||
| Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI | Q64819733 | ||
| Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? | Q69436285 | ||
| Iron in parkinsonian and control substantia nigra--a Mössbauer spectroscopy study | Q71438170 | ||
| Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP) | Q73853112 | ||
| The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element | Q79838827 | ||
| T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores | Q80837762 | ||
| Neuroaxonal dystrophy in calcium-independent phospholipase A2β deficiency results from insufficient remodeling and degeneration of mitochondrial and presynaptic membranes | Q84670136 | ||
| The Association of Iron and the Pathologies of Parkinson's Diseases in MPTP/MPP+-Induced Neuronal Degeneration in Non-human Primates and in Cell Culture | Q90206384 | ||
| Impaired iPLA2β activity affects iron uptake and storage without iron accumulation: An in vitro study excluding decreased iPLA2β activity as the cause of iron deposition in PLAN | Q91305443 | ||
| The role of iron in Parkinson's disease monkeys assessed by susceptibility weighted imaging and inductively coupled plasma mass spectrometry | Q91415119 | ||
| Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability | Q34534474 | ||
| PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron | Q34568479 | ||
| Characterization of PLA2G6 as a locus for dystonia-parkinsonism | Q34593410 | ||
| Phenotypic spectrum of patients with PLA2G6 mutation and PARK14 -linked parkinsonism | Q34624303 | ||
| The neuromelanin of human substantia nigra and its interaction with metals | Q34732635 | ||
| Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease | Q35165428 | ||
| PLA2G6 mutation underlies infantile neuroaxonal dystrophy | Q35221441 | ||
| Deficiency of Calcium-Independent Phospholipase A2 Beta Induces Brain Iron Accumulation through Upregulation of Divalent Metal Transporter 1 | Q35823121 | ||
| Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases | Q35994672 | ||
| Phosphorylation of α-Synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-Synuclein in the pathogenesis of Parkinson's Disease and related disorders | Q36015338 | ||
| Higher iron in the red nucleus marks Parkinson's dyskinesia. | Q36605028 | ||
| Mammalian iron metabolism and its control by iron regulatory proteins | Q36910294 | ||
| Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements | Q37402514 | ||
| Neuroaxonal dystrophy in PLA2G6 knockout mice | Q38464244 | ||
| Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice | Q38784740 | ||
| α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons. | Q38892026 | ||
| Iron mediated toxicity and programmed cell death: A review and a re-examination of existing paradigms | Q39034890 | ||
| Alpha-synuclein and iron: two keys unlocking Parkinson's disease. | Q39123736 | ||
| Iron Accumulation Is Not Homogenous among Patients with Parkinson's Disease | Q39763404 | ||
| Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice | Q40415532 | ||
| Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. | Q40470377 | ||
| An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys | Q42523521 | ||
| ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation | Q43121326 | ||
| Parkin regulates metal transport via proteasomal degradation of the 1B isoforms of divalent metal transporter 1. | Q43188522 | ||
| Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure | Q43735123 | ||
| Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease | Q44386905 | ||
| Generation of ferric iron links oxidative stress to α-synuclein oligomer formation | Q44498193 | ||
| Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys | Q44555302 | ||
| Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats | Q44697081 | ||
| Autosomal recessive juvenile parkinsonism Cys212Tyr mutation in parkin renders lymphocytes susceptible to dopamine- and iron-mediated apoptosis. | Q44800238 | ||
| Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. | Q45927167 | ||
| Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease | Q46485512 | ||
| Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. | Q46662757 | ||
| Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion | Q46718289 | ||
| Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers | Q46765690 | ||
| Species differences in the initial retrograde reaction of motor neurons | Q46799877 | ||
| Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains | Q46915316 | ||
| Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes | Q46990247 | ||
| MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease | Q47376890 | ||
| Association of freezing of gait with nigral iron accumulation in patients with Parkinson's disease. | Q47579143 | ||
| Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys | Q48171806 | ||
| Increased nigral iron content in postmortem parkinsonian brain | Q48182830 | ||
| P433 | issue | 2 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 181-187 | |
| P577 | publication date | 2020-02-05 | |
| P1433 | published in | Journal of Neural Transmission | Q15750921 |
| P1476 | title | Parkinson's disease and iron | |
| P478 | volume | 127 |
| Q99555756 | PET Imaging for Oxidative Stress in Neurodegenerative Disorders Associated with Mitochondrial Dysfunction | cites work | P2860 |
Search more.